INNATE PHARMA SA-SPONS ADR (IPHA) Stock News

Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York

Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

12 Health Care Stocks Moving In Monday's Pre-Market Session

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Innate Pharma Releases Its 2025 Financial Calendar

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

Innate Pharma Reports First Half 2024 Business Update and Financial Results

Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update

Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024

Number of Shares and Voting Rights of Innate Pharma as of June 10, 2024

Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are worth diving into on Monday and we have all of the latest news worth knowing about this morning!

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

Outcome of Innate Pharma’s 2024 Annual General Meeting

Innate Pharma: Clarification Regarding SAR443579 Designation

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients